New ICD-9 Codes at Pharmacy Point of Sale (POS: Drugs to treat Cystic Fibrosis

Effective July 1, 2013, the Division of Medicaid will require specific ICD-9 codes in the pharmacy point of sale (POS) system for the following drugs used to treat cystic fibrosis:

- Cayston (azetreonam)*
- Coly-Mycin M (colistimehtate sodium)*
- Pulmozyme (dornase alfa)*
- Tobi (tobramycin)*

*Existing users as of June 30, 2013 will be grandfathered

277.0	Cystic Fibrosis	
277.00	Cystic Fibrosis without mention meconium	
277.01	Cystic Fibrosis with meconium ileus	
277.02	Cystic Fibrosis with pulmonary manifestations	
277.03	CF with gastrointestinal manifestations	
277.09	Cystic Fibrosis with other manifestation	

Prescriber must write the validating ICD code on the prescription and no manual prior authorization is required. For the comprehensive list of valid ICD codes at POS, refer to Pharmacy Services' webpage at http://www.medicaid.ms.gov/Pharmacy.aspx, and select POS ICD-9 Codes. For other indications for the aforementioned drugs, please submit a prior authorization request. To process a claim, the pharmacy is to use the following procedure:

- (1) Submit the diagnosis code (on RX) in the field Diagnosis Code (492-DO)
- (2) Submit qualifier **Diagnosis Code Qualifier** (492-WE) = 01

Field	Field Name	Values Supported
492- WE	Diagnosis Code Qualifier	Required when Diagnosis used. 01 = ICD9
492-DO	Diagnosis Code	Required when diagnosis is needed for designated drug coverage.